We are live on ! Find out more

Omnicell

OMCL

Market cap $1.68B

36.88 USD

+0.93

2.59%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

36.88

0.00

0%

1 day

2.59%

5 days

0.03%

1 month

7.49%

3 months

-10.92%

6 months

-14.43%

Year to date

-18.3%

1 year

24.72%

5 years

-79.3%

10 years

13.02%

About: Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Employees: 3,485

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40.9%

Neutral 54.5%

Negative 4.5%

Omnicell, Inc. (OMCL) Q3 2026 Earnings Call Transcript

Omnicell, Inc. ( OMCL ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants David Unger - Vice President of Investor Relations Randall Lipps - Founder, Executive Chairman & CEO Nnamdi Njoku - President & COO Baird Radford Conference Call Participants Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Jessica Tassan - Piper Sandler & Co., Research Division Allen Lutz - BofA Securities, Research Division David Larsen - BTIG, LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Gene Mannheimer William Sutherland - StoneX Financial, Inc., Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Omnicell Third Quarter 2026 Financial Results Call.

Omnicell, Inc. (OMCL) Q3 2026 Earnings Call Transcript

Omnicell Q3 Earnings Call Highlights

Omnicell NASDAQ: OMCL reported third-quarter 2026 revenue and non-GAAP EBITDA above the high end of its prior guidance, while executives said the company is preparing to begin shipments of its Titan XT automated dispensing hardware and remains on track for first-half 2027 general availability of its OmniSphere cloud platform.

Omnicell Q3 Earnings Call Highlights

Zacks Investment Research

Here's What Key Metrics Tell Us About Omnicell (OMCL) Q3 Earnings

While the top- and bottom-line numbers for Omnicell (OMCL) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Omnicell (OMCL) Q3 Earnings

Zacks Investment Research

Omnicell (OMCL) Q3 Earnings and Revenues Top Estimates

Omnicell (OMCL) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.51 per share a year ago.

Omnicell (OMCL) Q3 Earnings and Revenues Top Estimates

Omnicell Announces Third Quarter 2026 Financial Results

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Third Quarter 2026 Financial Results.

Omnicell Announces Third Quarter 2026 Financial Results

Zacks Investment Research

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?

OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?

Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026.

Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026

Zacks Investment Research

Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research

Here's Why Omnicell (OMCL) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Omnicell (OMCL) is a Strong Value Stock

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

See News Rankings

Price charts implemented using Lightweight Charts™